OncoMed Pharmaceuticals News
Most Popular OncoMed Pharmaceuticals Story
Emerging Drug Developer: OncoMed Pharmaceuticals
OncoMed blueprints its future in cancer stem cells When Paul Hastings joined OncoMed Pharmaceuticals at the beginning of 2006, the fledgling developer had $3 million in the bank and some plans to
... Read more...Latest Headlines
- November 10, 2008
- November 4, 2008
- June 23, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
